We are live on ! Find out more
ZVSA

ZyVersa Therapeutics
ZVSA

Delisted

ZVSA was delisted on the 16th of July, 2025.

Back to rankings

2 hedge funds and large institutions have $124K invested in ZyVersa Therapeutics in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.26% less ownership

Funds ownership: 0.26% → 0% (-0.26%)

93% less funds holding

Funds holding: 29 → 2 (-27)

93% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 29

100% less capital invested

Capital invested by funds: $73.3M → $124K (-$73.1M)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
2
Holders Change
-27
Holders Change %
-93.1%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
2
Increased
–
Reduced
–
Closed
29
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
+$537K
2
CL
CSS LLC
Illinois
+$123K

Top Sellers

Rank Fund Capital Flow
1
RA
RiverPark Advisors
New York
-$7M
2
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
-$6.99M
3
CM
Cohanzick Management
New York
-$6.94M
4
SCM
Saba Capital Management
New York
-$5.97M
5
YCM
Yakira Capital Management
Connecticut
-$5.53M

ZVSA Hedge Fund Activity: Q4 2022 in Review

2 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in ZyVersa Therapeutics (ZVSA) for Q4 2022, worth a combined $124K — down 100% from $73.3M a quarter earlier.

Sellers outnumbered buyers: 29 funds closed out of ZVSA and 2 opened new positions — a net loss of 27 holders — while 0 trimmed existing stakes and 0 added.

The largest buyer was Goldman Sachs, opening a new position worth an estimated $537K. The largest seller was RiverPark Advisors, exiting entirely with an estimated $7M sold.

  • 2 institutional investors held ZyVersa Therapeutics (ZVSA) as of Q4 2022, down from 29 in Q3 2022.
  • Funds reported $124K of ZyVersa Therapeutics stock for Q4 2022, down 100% quarter-over-quarter.
  • 2 funds opened new ZyVersa Therapeutics positions in Q4 2022 and 29 closed out, a net change of -27 holders.
  • The largest ZyVersa Therapeutics buyer in Q4 2022 was Goldman Sachs, an estimated $537K added.
  • The largest ZyVersa Therapeutics seller in Q4 2022 was RiverPark Advisors, an estimated $7M sold.

Based on aggregated 13F filings for Q4 2022.